Pfizer says its former global marketing director emailed and copied hundreds of documents on product launch plans and steps to obtain government approvals before leaving the company in January.

The big pharma is moving into a new therapy area – dermatology – as part of a three-pronged strategy in Inflammation & Immunology that also includes rheumatology and gastroenterology. Pfizer’s first product for dermatology, crisaborole for atopic dermatitis, could launch next year.

The first drugs expected to face US Medicare drug price negotiations, according to a new analysis, will have had an average commercial life span of 15 years.